Novalar Pharmaceuticals has entered into an agreement to sell its OraVerse injection drug to a dental pharmaceutical company. The product rapidly reverses lingering lip and tongue numbness that results from local dental anesthesia.

Novalar Pharmaceuticals has entered into an agreement to sell its OraVerse injection drug to a dental pharmaceutical company. The product rapidly reverses lingering lip and tongue numbness that results from local dental anesthesia. Photo by Photo courtesy of Novalar Pharmaceuticals

NOVALAR PHARMACEUTICALS INC.

President and CEO: Donna Janson.

Financial information: Would not disclose.

No. of local employees: 12.

Investors: New Enterprise Associates, Domain Associates L.L.C., SR One and Montreux Equity Partners.

Headquarters: Carmel Valley.

Year founded: 2000.

Company description: The privately held dental specialty pharmaceutical company developed an FDA-approved injection drug to rapidly reverse lingering lip and tongue numbness that results from local dental anesthesia.

After finding a buyer for its only product, local dental biotech company Novalar Pharmaceuticals Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129